Showing posts with label Trasylol Lawyer. Show all posts
Showing posts with label Trasylol Lawyer. Show all posts

Tuesday, February 19, 2008

Trasylol Lawyer | Kidney Failure Attorney | Trasylol Renal Failure

The Trasylol lawyer at Flynn and Associates has learned that Trasylol is associated with kidney failure and other renal failure related Trasylol injuries. The side effects of Trasylol include kidney or renal failure and other kidney related injuries. Your Trasylol attorney can help you obtain the compensation that you deserve for your Trasylol related kidney failure injuries. Trasylol is marketed by Bayer and is used during heart surgery. If you have suffered a Trasylol related kidney injury, contact your Trasylol lawyer today to find out if your Trasylol attorney can help you obtain legal compensation for your Trasylol kidney failure or renal related Trasylol injuries.

Heart surgery patients and doctors should be aware of serious Trasylol side effects recently discovered in a January 2006 study published in the New England Journal of Medicine . Recent evidence suggests that Trasylol doubles the risk of kidney damage, heart attack, heart failure, stroke, brain disease, and other serious and life-threatening Trasylol side effects.

Trasylol (aprotinin), made by Bayer Pharmaceuticals, was approved by the FDA in December 1993 to reduce bleeding and the need for blood transfusion in patients undergoing heart surgery. The serious risk of Trasylol side effects had not fully been disclosed until the publication of this recent study, after over a decade of this medication''s use.

The risk of Trasylol side effects are so great that the lead author of the study, Dr. Dennis Mangano of California''s Ischemic Research and Education Foundation, has compared them to Vioxx side effects. "It''s like a ''Vioxx II'' but it''s a little bit different. The frequency of adverse events we see is far greater with Trasylol than with Vioxx ," states Mangano. He also expressed concern about the sheer number of people who have taken Trasylol without knowing the serious risk of Trasylol side effects.

The Trasylol lawyers at Flynn and Associates can help you navigate the complex legal maze that will be presented as an obstruction to your compensation for your Trasylol injury. You should be aware that you should contact your Trasylol attorney immediately to discuss your case. This is because the statute of limitations could run soon on your Trasylol case, forever barring you from recovery for your Trasylol injury. Contact one of the Trasylol lawyers at Flynn and Associates immediately to discuss your Trasylol injury case.

Trasylol Lawyer

Friday, September 28, 2007

Trasylol Attorney | Trasylol Lawyer

Trasylol®: A Blood-Clotting Drug

Trasylol® is an FDA-approved blood-clotting drug used to reduce bleeding and to lessen the need for blood transfusions for people undergoing cardiopulmonary bypass (CPB) for coronary artery bypass graft (CABG) surgery. Trasylol® is the brand name that the manufacturer Bayer Healthcare Pharmaceuticals uses; the generic name of this drug is aprotonin. Trasylol® use has been linked to increases in the risk of stroke, encephalopathy, heart failure, and kidney damage. If you’ve had surgery and then experienced one of these complications, you should contact your physician to find out whether Trasylol® was used during the procedure.

FDA Public Health Advisory Regarding Trasylol®

The FDA approved Trasylol® in 1993 for the heart surgery procedures described above. In February 2006, the FDA issued a Public Health Advisory regarding Trasylol®, stating that they’re performing a new safety evaluation of Trasylol®. Although the FDA approved Trasylol® only for use in specific cardiac surgeries, Trasylol® is now also used during some other types of surgeries, such as orthopedic surgery. The FDA advisory describes the possible adverse effects of Trasylol® use and reminds physicians of the approved and unapproved uses of Trasylol®, and of the patient characteristics that can increase the risks associated with Trasylol® use.

The highly respected New England Journal of Medicine published a study in early 2006 concluding that the data obtained regarding Trasylol® and end-organ damage indicate that further use of Trasylol® is not “prudent.”